Hydroxychloroquine shows potential survival benefit in systemic sclerosis
Systemic sclerosis (SSc) patients using hydroxychloroquine have reduced mortality, although they appear to have a higher prevalence of pulmonary hypertension compared with their peers who do not use the drug, according to a retrospective study.
